{"id":15172,"date":"2025-10-09T16:18:06","date_gmt":"2025-10-09T14:18:06","guid":{"rendered":"https:\/\/semmelweis.hu\/pharmacology\/?page_id=15172"},"modified":"2026-02-09T13:13:31","modified_gmt":"2026-02-09T12:13:31","slug":"translational-research-and-innovation-in-the-diagnosis-and-treatment-of-ischemic-heart-disease-and-its-comorbidities","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/pharmacology\/en\/research\/grants\/translational-research-and-innovation-in-the-diagnosis-and-treatment-of-ischemic-heart-disease-and-its-comorbidities\/","title":{"rendered":"Translational research and innovation in the diagnosis and treatment of ischemic heart disease and its comorbidities"},"content":{"rendered":"
Translational research and innovation in the diagnosis and treatment of ischemic heart disease and its comorbidities<\/strong><\/div>\n
\u00a0<\/div>\n\n\n\n\n\n\n
Grant:<\/td>\nT\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program 2021<\/td>\n<\/tr>\n
Amount of support:<\/td>\n332.500.000 HUF<\/td>\n<\/tr>\n
Duration:<\/td>\n2021.08.01-2025.12.31<\/td>\n<\/tr>\n
Principal investigator:<\/td>\nP\u00e9ter Ferdinandy, MD, PhD, DSc, MBA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Summary <\/strong><\/p>\n

For decades, our institute has been at the international forefront of research into ischemia\/reperfusion myocardial injury in the presence of comorbidities. We were the first to show that hyperlipidemia impairs myocardial stress adaptation.<\/p>\n

Inflammatory processes play a central role in the development and progression of cardiovascular disease. Heart failure with preserved ejection fraction (HFpEF) is typically caused by the presence of several cardiometabolic comorbidities, such as diabetes, obesity, and hypertension. Although modulation of inflammation in oncological therapies is successful, the enhanced immune response to immune checkpoint inhibitory anticancer therapies may accelerate atherosclerosis and increase cardiovascular risk. Therefore, we aim to investigate the inflammatory mechanisms in in vitro<\/em> hypercholesterolemic cell culture models, in vivo<\/em> HFpEF animal models, and human cardiac tissue samples.<\/p>\n

Our research also tests new cardioprotective molecules, including RNA therapeutics, which have significantly progressed in recent years. We have previously identified cardioprotective non-coding microRNAs as drug candidates. Analysis of microRNA-mRNA networks can reveal cardiac ischemia\/reperfusion injury following myocardial ischemia, remodeling, and transcriptome changes. This unbiased omics approach is key to identifying novel regulators of cardioprotection. Our study aims to identify hypercholesterolemia-induced miRNA pathway alterations by unbiased network analysis.<\/p>\n

Participating leading researchers, collaboration partners, universities, companies <\/strong><\/p>\n

The project is led by P\u00e9ter Ferdinandy, MD, PhD, DSc, MBA, Director of the Department of Pharmacology and Pharmacotherapy at Semmelweis University, Deputy Rector for Science and Innovation. The project will use samples collected and stored in the Heart Transplant Biobank of the Heart and Vascular Research Center (VSZ\u00c9K) of Semmelweis University. Among the staff of VSZ\u00c9K, Prof. B\u00e9la Merkely, Rector of Semmelweis University, and Dr. Tam\u00e1s Radovits, habilitated associate professor, are the main contributors to the research. We also collaborate with the Department of Genetics, Cell and Immunobiology, and the Department of Biophysics at Semmelweis University.<\/p>\n

Applied methods and tools <\/strong><\/p>\n

An in vitro<\/em> hypercholesterolemia cell culture model will be established. We investigate the response to inflammatory stimuli in the presence\/absence of hypercholesterolemic supplementation in a human monocyte cell line (THP1-ASC-GFP). We will analyze the changes in the expression of immune checkpoints and the effect of their inhibitors on cell phenotype. A mouse model of HFpEF will be induced by a high-fat diet and nitric oxide synthase inhibition in C57BL\/6J mice, followed by treatment with anti-PD1 or control antibody and echocardiography to assess cardiac function, with particular attention to hypertrophy and diastolic dysfunction.<\/p>\n

The effect of the identified microRNAs will first be tested in vitro on cardiac myocytes, and then the tissue distribution and clearance of potentially protective microRNAs (protectomiR) will be investigated in vivo<\/em> in animal models. The complex effects of protective microRNAs on target RNAs will be examined by qPCR, digital droplet PCR, and RNA in situ hybridization.<\/p>\n

Pictures<\/strong><\/p>\n\r\n [slb_exclude]\r\n

\r\n
\r\n \r\n\t\t\t\t
\"Fluorescence<\/a><\/div>\r\n <\/span>\r\n\r\n <\/div>\r\n\r\n\t\t\t
\r\n\t\t\t\t
\r\n
\r\n\t\t\t\t\t

Gal\u00e9ria<\/h3>\r\n\t\t\t\t\t
\r\n\r\n\t\t\t\t\t\t
2<\/span>k\u00e9p<\/div>\r\n <\/div> <\/div>\r\n \r\n\t\t\t\t\t
\"Cardiac<\/a><\/div>\r\n <\/span>\r\n \r\n\t\t\t\t\t
\"\"<\/div>\r\n <\/span>\r\n\r\n <\/div>\r\n\r\n <\/div>\r\n\r\n \r\n <\/div>\r\n\r\n [\/slb_exclude]\r\n\t\n

Mission and benefits<\/strong><\/p>\n

We aim to investigate inflammatory processes in the development and progression of cardiovascular disease and identify hypercholesterolemia-induced miRNA pathway alterations in various in vitro <\/em>and in vivo<\/em> models. The main general objectives of the proposal are:<\/p>\n

    \n
  1. to facilitate the clinical translation and commercialization of novel therapeutic research and development projects,<\/li>\n
  2. to support international excellence: to maximize the involvement and funding of national and foreign PhD students and young researchers through the support of MD-PhD and the facilitation of participation in the Cooperative PhD program,<\/li>\n
  3. maintenance of core facilities and acquisition of new equipment in synergy with the plans to establish the SE Science Park.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Translational research and innovation in the diagnosis and treatment of ischemic heart disease and its comorbidities \u00a0 Grant: T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program 2021 Amount of support: 332.500.000 HUF Duration: 2021.08.01-2025.12.31 Principal investigator: P\u00e9ter Ferdinandy, MD, PhD, DSc, MBA   Summary For decades, our institute has been at the international forefront of research into ischemia\/reperfusion myocardial injury …<\/p>\n","protected":false},"author":102427,"featured_media":0,"parent":15124,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-15172","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/15172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/users\/102427"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/comments?post=15172"}],"version-history":[{"count":3,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/15172\/revisions"}],"predecessor-version":[{"id":15264,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/15172\/revisions\/15264"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/pages\/15124"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/media?parent=15172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/categories?post=15172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/pharmacology\/wp-json\/wp\/v2\/tags?post=15172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}